Recent Updates
Recently added Catalysts
OGN Positive Sentiment

Organon Announces Quarterly Dividend

Friday, July 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Organon has declared a quarterly dividend of $0.02 per share, reflecting its commitment to shareholder returns. The dividend will be payable on September 10, 2026, to stockholders of record by August 14, 2026. This announcement underscores the company's ongoing financial health and dedication to its investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Organon is committed to delivering impactful medicines.
  • The declaration of a dividend indicates financial stability.
  • The company continues to engage with its shareholders positively.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+54%
120-day peak, hindsight
Typical move
3.1%
average across 5 past catalysts
Lead asset
MK0653A, ezetimibe simvastatin
Phase 3 · Hypercholesterolemia

Full Press Release Details

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the company’s Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock. The dividend is payable on September 10, 2026, to stockholders of record at the close of business on August 14, 2026. About Organon Organon (NYSE: OGN) is a global h

Frequently Asked Questions

What is the amount of Organon's quarterly dividend?

Organon's quarterly dividend is $0.02 per share.

When will the dividend be payable?

The dividend will be payable on September 10, 2026.

Who is eligible for the dividend?

Stockholders of record at the close of business on August 14, 2026, are eligible.

What does this dividend declaration indicate?

It indicates Organon's financial stability and commitment to shareholders.

ShareAdd on Google
Tags: OGN Viatris Investor Conferences Healthcare Organon dividend shareholder returns financial stability
Last updated: Jul 31, 2026

Biotech snapshot

Cash runway
$1116M liquidity · $0M/mo burn
Low dilution risk
Lead asset
MK0653A, ezetimibe simvastatinPhase 3
Hypercholesterolemia →

Catalyst track record

+54%
best trade around OGN's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for OGN.

See every catalyst's timing & PoA →